API
< Back to all clusters
[TECHNOLOGY] · Russia · 2 sources

started · updated

Russian scientists develop bioartificial liver using patient cells

Russian biotechnology company Artcellence, in collaboration with the M. F. Vladimirsky Moscow Regional Clinical Research Institute, is developing a bioartificial liver designed to support patients with liver failure. The technology utilizes a patient's own blood to obtain induced pluripotent stem cells, which are then transformed into cells capable of performing hepatic functions.

Unlike a permanent implant, this device is an extracorporeal support system that connects to the patient to clean the blood, maintain metabolism, and synthesize proteins. By using the patient's own biological material, the project aims to reduce the risk of immune system rejection.

Clinical trials are scheduled to begin in Moscow in early 2027. The production of these systems is expected to be established in the Technopolis Moscow special economic zone, with a planned capacity of approximately 1,600 units per year. In its initial stage, the device will serve as temporary support for patients awaiting transplants or recovering from severe organ failure, with the long-term goal of becoming a complete alternative to transplantation.

Entities

Artcellence · M. F. Vladimirsky Moscow Regional Clinical Research Institute · Moscow · Shinya Yamanaka · Technopolis Moscow